Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, Bernstein JA, Brehler R, Chu CY, Chung WH, Danilycheva I, Grattan C, Hébert J, Katelaris C, Makris M, Meshkova R, Savic S, Sinclair R, Sitz K, Staubach P, Wedi B, Löffler J, Barve A, Kobayashi K, Hua E, Severin T, Janocha R. Maurer M, et al. Among authors: brehler r. N Engl J Med. 2019 Oct 3;381(14):1321-1332. doi: 10.1056/NEJMoa1900408. N Engl J Med. 2019. PMID: 31577874 Free article. Clinical Trial.
[In vitro allergy diagnosis in dermatology].
Brehler R, Wedi B. Brehler R, et al. Hautarzt. 2010 Nov;61(11):935-7. doi: 10.1007/s00105-010-2004-x. Hautarzt. 2010. PMID: 20972531 German. No abstract available.
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Maurer M, et al. Among authors: brehler r. J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038. Epub 2011 Jun 2. J Allergy Clin Immunol. 2011. PMID: 21636116 Clinical Trial.
Delayed pressure urticaria - dapsone heading for first-line therapy?
Grundmann SA, Kiefer S, Luger TA, Brehler R. Grundmann SA, et al. Among authors: brehler r. J Dtsch Dermatol Ges. 2011 Nov;9(11):908-12. doi: 10.1111/j.1610-0387.2011.07749.x. Epub 2011 Jul 20. J Dtsch Dermatol Ges. 2011. PMID: 21771275 English, German.
[Specific immunotherapy].
Brehler R, Wedi B. Brehler R, et al. Hautarzt. 2017 Apr;68(4):262-264. doi: 10.1007/s00105-017-3955-y. Hautarzt. 2017. PMID: 28275810 German. No abstract available.
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M. Metz M, et al. Among authors: brehler r. Theranostics. 2017 Mar 6;7(5):1266-1276. doi: 10.7150/thno.18304. eCollection 2017. Theranostics. 2017. PMID: 28435464 Free PMC article. Clinical Trial.
Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.
Metz M, Torene R, Kaiser S, Beste MT, Staubach P, Bauer A, Brehler R, Gericke J, Letzkus M, Hartmann N, Erpenbeck VJ, Maurer M. Metz M, et al. Among authors: brehler r. Allergy. 2019 Jan;74(1):141-151. doi: 10.1111/all.13547. Epub 2018 Oct 15. Allergy. 2019. PMID: 29974963 Clinical Trial.
160 results